Contributions of Humoral and Cellular Immunity to Vaccine-induced Protection in Humans

Overview

Journal Virology

Specialty Microbiology

Date 2011 Jan 11

PMID 21216425

Citations 125

Authors

Ian J Amanna

Mark K Slifka

Affiliations

Soon will be listed here.

Abstract

Vaccines play a vital role in protecting the host against infectious disease. The most effective licensed vaccines elicit long-term antigen-specific antibody responses by plasma cells in addition to the development of persisting T cell and B cell memory. The relative contributions of these different immune cell subsets are context-dependent and vary depending on the attributes of the vaccine (i.e., live/attenuated, inactivated, and subunit) as well as the biology of the pathogen in question. For relatively simple vaccines against bacterial antigens (e.g., tetanus toxin) or invariant viruses, the immunological correlates of protection are well-characterized. For more complex vaccines against viruses, especially those that mutate or cause latent infections, it is more difficult to define the specific correlates of immunity. This often requires observational/natural history studies, clinical trials, or experimental evaluation in relevant animal models in order for immunological correlates to be determined or extrapolated. In this review, we will discuss the relative contributions of virus-specific T cell and B cell responses to vaccine-mediated protection against disease.

Citing Articles

Q Fever Vaccines: Unveiling the Historical Journey and Contemporary Innovations in Vaccine Development.

Christodoulou M, Papagiannis D Vaccines (Basel). 2025; 13(2).

PMID: 40006698 PMC: 11861857. DOI: 10.3390/vaccines13020151.

Pivotal role of virulence genes in pathogenicity and vaccine development.

Elbehiry A, Marzouk E, Abalkhail A, Sindi W, Alzahrani Y, Alhifani S Front Med (Lausanne). 2025; 11():1523991.

PMID: 39850097 PMC: 11756510. DOI: 10.3389/fmed.2024.1523991.

Chronic inflammation degrades CD4 T cell immunity to prior vaccines in treated HIV infection.

Kiessling M, Cole J, Kubel S, Klein P, Korn K, Henry A Nat Commun. 2024; 15(1):10200.

PMID: 39587133 PMC: 11589758. DOI: 10.1038/s41467-024-54605-3.

Determination of immunogenicity of an inactivated ND-vaccine developed experimentally with Newcastle disease virus (Genotype VII.2) local isolates of Bangladesh.

Haque M, Haque M, Parvin M, Kamal M, Islam T, Sadekuzzaman M Front Immunol. 2024; 15:1482314.

PMID: 39569197 PMC: 11576377. DOI: 10.3389/fimmu.2024.1482314.

Immunoinformatics Design of a Multiepitope Vaccine (MEV) Targeting : A Novel Computational Approach.

Naorem R, Pangabam B, Bora S, Fekete C, Teli A Pathogens. 2024; 13(10).

PMID: 39452787 PMC: 11509883. DOI: 10.3390/pathogens13100916.

References

Lambert P, Liu M, Siegrist C . Can successful vaccines teach us how to induce efficient protective immune responses?. Nat Med. 2005; 11(4 Suppl):S54-62. DOI: 10.1038/nm1216. View

Mitra-Kaushik S, Cruz J, Stern L, Ennis F, Terajima M . Human cytotoxic CD4+ T cells recognize HLA-DR1-restricted epitopes on vaccinia virus proteins A24R and D1R conserved among poxviruses. J Immunol. 2007; 179(2):1303-12. DOI: 10.4049/jimmunol.179.2.1303. View

Casadevall A . Passive antibody therapies: progress and continuing challenges. Clin Immunol. 1999; 93(1):5-15. DOI: 10.1006/clim.1999.4768. View

Pierce S, Liu W . The tipping points in the initiation of B cell signalling: how small changes make big differences. Nat Rev Immunol. 2010; 10(11):767-77. PMC: 3406597. DOI: 10.1038/nri2853. View

Manz R, Thiel A, Radbruch A . Lifetime of plasma cells in the bone marrow. Nature. 1997; 388(6638):133-4. DOI: 10.1038/40540. View

Kreil T, Burger I, Bachmann M, Fraiss S, Eibl M . Antibodies protect mice against challenge with tick-borne encephalitis virus (TBEV)-infected macrophages. Clin Exp Immunol. 1997; 110(3):358-61. PMC: 1904814. DOI: 10.1046/j.1365-2249.1997.4311446.x. View

. Rabies vaccines. WHO position paper. Wkly Epidemiol Rec. 2007; 82(49-50):425-35. View

Rees L, Ayoub O, Haverson K, Birchall M, Bailey M . Differential major histocompatibility complex class II locus expression on human laryngeal epithelium. Clin Exp Immunol. 2003; 134(3):497-502. PMC: 1808879. DOI: 10.1111/j.1365-2249.2003.02301.x. View

Darce J, Arendt B, Wu X, Jelinek D . Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol. 2007; 179(11):7276-86. DOI: 10.4049/jimmunol.179.11.7276. View

10.

Valmori D, Sabbatini A, Lanzavecchia A, Corradin G, Matricardi P . Functional analysis of two tetanus toxin universal T cell epitopes in their interaction with DR1101 and DR1104 alleles. J Immunol. 1994; 152(6):2921-9. View

11.

Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R . Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol. 2003; 171(10):4969-73. DOI: 10.4049/jimmunol.171.10.4969. View

12.

Nardelli-Haefliger D, Wirthner D, Schiller J, Lowy D, Hildesheim A, Ponci F . Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst. 2003; 95(15):1128-37. DOI: 10.1093/jnci/djg018. View

13.

Li S, Chan I, Matthews H, Heyse J, Chan C, Kuter B . Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J. 2002; 21(4):337-42. DOI: 10.1097/00006454-200204000-00014. View

14.

Matter L, Kogelschatz K, Germann D . Serum levels of rubella virus antibodies indicating immunity: response to vaccination of subjects with low or undetectable antibody concentrations. J Infect Dis. 1997; 175(4):749-55. DOI: 10.1086/513967. View

15.

Tizard I . Grease, anthraxgate, and kennel cough: a revisionist history of early veterinary vaccines. Adv Vet Med. 1999; 41:7-24. DOI: 10.1016/s0065-3519(99)80005-6. View

16.

Nie Y, Waite J, Brewer F, Sunshine M, Littman D, Zou Y . The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J Exp Med. 2004; 200(9):1145-56. PMC: 2211858. DOI: 10.1084/jem.20041185. View

17.

HYLAND L, SANGSTER M, Sealy R, Coleclough C . Respiratory virus infection of mice provokes a permanent humoral immune response. J Virol. 1994; 68(9):6083-6. PMC: 237018. DOI: 10.1128/JVI.68.9.6083-6086.1994. View

18.

Munz C, Bickham K, Subklewe M, Tsang M, Chahroudi A, Kurilla M . Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med. 2000; 191(10):1649-60. PMC: 2193162. DOI: 10.1084/jem.191.10.1649. View

19.

Amanna I, Messaoudi I, Slifka M . Protective immunity following vaccination: how is it defined?. Hum Vaccin. 2008; 4(4):316-9. PMC: 6776428. DOI: 10.4161/hv.4.4.5751. View

20.

Lin Y, Chang M, Ni Y, Hsu H, Chen D . Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis. 2003; 187(1):134-8. DOI: 10.1086/345871. View